

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)



(10) International Publication Number
WO 2021/258016 A1

(51) International Patent Classification:

C12N 5/0783 (2010.01) A61P 35/00 (2006.01)
A61K 35/17 (2014.01) C07K 14/705 (2006.01)
A61K 39/395 (2006.01) C07K 14/735 (2006.01)
A61K 45/06 (2006.01) C07K 14/54 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2021/038134

(22) International Filing Date:

18 June 2021 (18.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/041,672 19 June 2020 (19.06.2020) US

(71) Applicant: **FATE THERAPEUTICS, INC.** [US/US];
12278 Scripps Summit Drive, San Diego, CA 92131 (US).

(72) Inventors: **VALAMEHR, Bahram**; 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (US).
GOODRIDGE, Jode; 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (US). **BJORDAHL, Ryan**; 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (US).

(74) Agent: **GIERING, Jeffery, C.**; Greenberg Traurig, LLP, 18565 Jamboree Road, Suite 500, Irvine, California 92612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINING IPSC-DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE

(57) Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors or additional cells in combination therapies.



WO 2021/258016 A1